Language

CAS No. 864070-44-0 | Empagliflozin

Name: Empagliflozin CAS No. 864070-44-0 MF:C23H27ClO7 MW:450.91 Purity:98% Package: 5g,25g,200g,500g,1kg Worldwide Delivery

Categories：

Pharmaceutical Intermediates

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

Introduction and application of CAS No. 864070-44-0 | Empagliflozin

Synonyms:Empaglifloin;

Empagliflozin API;

BI-10773;

CS-798;

EMPAGLIFLBZIN;

EMpagliflozin;

Specification:

ITEMS	SPECIFICATION
CAS	864070-44-0
MF	C23H27ClO7
MW	450.91
Flash point	356℃
Boiling point	665℃
Density	1.398
Acidity coefficient	13.23±0.70
Color	White
Solubility	Insoluble in water; ≥20.75 mg/mL in DMSO; ≥7.06 mg/mL, ethanol solution, ultrasound
Form	Solid
Storage condition	2-8°C

application:

Empagliflozin is used to treat 2 adults with diabetes who have failed to achieve adequate glycemic control through diet and exercise, to improve glycemic control. It should not be used to treat people with type 1 diabetes, people with elevated ketones in the blood or urine (diabetic ketoacidosis), people with severe kidney damage, end-stage kidney disease, and people on dialysis.

Pharmacological effects:

Under physiological conditions, the kidneys maintain blood sugar balance in the body by filtering and reabsorbing glucose into the circulation system. Glucose enters the blood through the renal tubule lumen and must be coordinated by a glucose cotransporter. SGLT2 serves as a sodium glucose cotransporter in the glucose cotransporter. A form of cotransporter that blocks the reabsorption of glucose by the proximal convoluted tubule, reduces glucose reabsorption by the kidney, and increases the excretion of glucose in the urine, thereby reducing plasma glucose levels. Moreover, this hypoglycemic effect does not depend on β-cell function and is not affected by insulin resistance.

Package and transportation :

Package: 10g,25g,50g,100g,250g